Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Massachusetts, Worcester
• Collaborator: GlaxoSmithKline
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

1. Overweight but otherwise in good general health.

2. Age 18 - 55 years.

3. Normal glucose tolerance.

4. Stable weight with BMI (27-44).

5. Stable medication use for the preceding month.

6. BP < 150/90.

7. Negative pregnancy test (*HCG), if female and of childbearing potential.

8. Practicing, and willing to continue to practice appropriate contraception throughout the study if a female of childbearing potential.

Exclusion Criteria:

1. Serious medical illness.

2. Pregnancy.

3. Tobacco use within the past 6 months.

4. Prior or current treatment with a thiazolidinedione.

5. Patients who have received an investigational drug in the past 30 days.

6. Use of systemic corticosteroids.

7. Known or suspected allergy to Rosiglitazone or any component of the preparation